Skip to main content

The United States Food and Drug Administration (FDA) has approved Genentech’s agent Avastin (bevacizumab) for the treatment of advanced breast cancer. Specifically, the indications include Avastin, in combination with Taxol® (paclitaxel) for patients with metastatic human epidermal receptor 2-negative (HER2-negative) breast cancer who have not received prior chemotherapy for metastatic disease.

The somewhat surprising approval comes following the ODAC recommendation for rejection of this indication.

The approval was prompted by an improvement in progression-free survival of 5.5 months with Avastin/Taxol over Taxol alone, with no demonstration of a survival improvement with Avastin.

Avastin is already approved for colon and lung cancer.

Scroll to Continue

Recommended Articles

Image placeholder title

Relatlimab Anti-LAG-3 Antibody

Is combination immunotherapy with the anti-LAG-3 antibody relatlimab and Opdivo the next advance in melanoma treatment?

Image placeholder title

Blood Cancers and COVID-19 - What You Need to Know

COCID-19 puts individuals with leukemia, lymphoma, myeloma and MPN's at risk - learn how to optimize your care.